OCGN
NASDAQOcugen Inc.
Price$1.68+0.00 (+0.00%)
2026-01-202026-04-23
News · 26 weeks47-56%
2025-10-262026-04-19
Mix2790d
- Other10(37%)
- SEC Filings9(33%)
- Earnings2(7%)
- Insider2(7%)
- Analyst2(7%)
- Leadership1(4%)
- Other1(4%)
Latest news
25 items- PROcugen to Present at April 2026 Investor and Industry ConferencesMALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy. "I look forward to sharing our story with new audiences and building enthusiasm f
- SECSEC Form PRER14A filed by Ocugen Inc.PRER14A - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form PRE 14A filed by Ocugen Inc.PRE 14A - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form SCHEDULE 13G filed by Ocugen Inc.SCHEDULE 13G - Ocugen, Inc. (0001372299) (Subject)
- PRBiotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsAVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB:AVAI), Lineage Cell Therapeutics, Inc. (NYSE:LCTX), Ocugen, Inc. (NASDAQ:OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Longeveron Inc. (NASDAQ:LGVN)Key Takeaways:Avaí Bio (OTCQB:AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will present their latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely recognized for discovering the Klotho gene [1
- INSIDERSEC Form 4 filed by Zhang Junge4 - Ocugen, Inc. (0001372299) (Issuer)
- PROcugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt DiseaseGARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathies MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retino
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ocugen Inc.SCHEDULE 13G/A - Ocugen, Inc. (0001372299) (Subject)
- SECOcugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationOptimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectivelyNo serious adverse events and no adverse events of special interest related to OCU410 reported to date MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene
- PROcugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic AtrophyMALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026. KOLs leading the webcast include: Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocu
- SECOcugen Inc. filed SEC Form 8-K: Other Events8-K - Ocugen, Inc. (0001372299) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Ocugen with a new price targetCanaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00
- ANALYSTOppenheimer initiated coverage on Ocugen with a new price targetOppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00
- INSIDERNew insider Johnson-Greene Treerita Essalima claimed ownership of 500,350 shares (SEC Form 3)3 - Ocugen, Inc. (0001372299) (Issuer)
- SECSEC Form S-8 filed by Ocugen Inc.S-8 - Ocugen, Inc. (0001372299) (Filer)
- SECSEC Form 10-K filed by Ocugen Inc.10-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- SECOcugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)
- PROcugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial ResultsEnrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission.OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026. First regional licensing agreement for OCU400 in 2025 initiates strategic partnership strategy
- PRInvestors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B MilestoneNext-generation cellular therapies and regenerative medicine drive exponential expansionNEW YORK, March 3, 2026 /CNW/ -- Market News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for ways to stay healthier, more energetic, and more youthful. What was once considered a niche cosmetic category has evolved into a major healthcare and biotech opportunity. Industry forecasts project the broader anti-aging market could surpass $420 billion by 2030, growing at an estimated 8–9% compound annual growth rate (CAGR). This growth is being fueled by rising healthcare awareness, advances in biotechnology, and increased de
- PROcugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis PigmentosaEnrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RPPositive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically meaningful, approximately 2-line LLVA gain, reinforcing durable gene-agnostic benefit MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene ther
- PROcugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec
- SECOcugen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Ocugen, Inc. (0001372299) (Filer)